Written by Healing Sky Editorial Team. Clinically reviewed by Cynthia Abraham D.O.
For people managing opioid use disorder, one of the most common questions is whether a long-acting buprenorphine injection is the right next step. Understanding how BRIXADI works and what maintenance treatment actually looks like can help patients and families make an informed choice.
Opioid use disorder (OUD) is a chronic medical condition that affects the brain's reward system and stress circuits. Effective treatment isn't about willpower; it's about giving the brain time and support to heal. Buprenorphine is a proven medication for OUD (MOUD). When delivered in a long-acting injection, it provides steady support without the ups and downs of daily dosing.
Long-acting injectable buprenorphine removes several practical obstacles that can derail daily oral treatment. There are no pills or films to remember, lose, or have stolen. Blood levels stay more consistent, which often means fewer cravings and a steadier mood. Because the dose is administered in-clinic, the risk of diversion or misuse is lower. Regular injection visits also build in structured contact with a care team, which supports accountability without requiring extra effort from the patient.
BRIXADI is an FDA-approved, long-acting buprenorphine injection used to treat moderate to severe opioid use disorder in adults. (fda.gov) It is a maintenance medication designed to reduce cravings and block the intense effects of other opioids. A healthcare professional gives the injection subcutaneously in areas such as the abdomen, thigh, upper arm, or buttock. (brixadihcp.com) BRIXADI comes in both weekly and monthly formats; the clinician selects a dose and schedule based on the patient's needs and adjusts over time. Like all MOUD, it is one part of a comprehensive plan that should also include counseling, behavioral therapies, and support for mental and physical health.
Buprenorphine is a partial opioid agonist. It binds strongly to opioid receptors in the brain but activates them only partially. That partial activation is powerful enough to control withdrawal and cravings without producing the intense high of full opioids, and it carries a ceiling effect on respiratory depression that improves safety.
BRIXADI uses an extended-release technology that forms a small, temporary depot under the skin. (brixadihcp.com) From there, buprenorphine is released slowly over a week or a month, depending on the formulation. Consistent blood levels help prevent the peaks and dips that can trigger cravings, and sustained receptor occupancy can blunt or block the effects of other opioids if they are used.
Most adults with moderate to severe OUD can consider BRIXADI, whether they are new to treatment or already stabilized on sublingual buprenorphine. It is worth discussing with a clinician when daily dosing is difficult to maintain, when medication has been lost, stolen, or misused at home, or when a patient wants a discreet option that reduces pharmacy visits. Patients who are stable on sublingual buprenorphine and want a simpler maintenance plan are also good candidates, as are those who would benefit from the flexibility of starting weekly before moving to monthly dosing.
Medical factors also shape the decision: liver health, other medications, pregnancy plans, and co-occurring mental health conditions all factor in. The best treatment is the one a patient can continue safely.
The first visit focuses on a careful assessment covering opioid history, prior treatments, medical conditions, mental health, and recovery goals. The clinician explains how BRIXADI works, expected benefits, and possible side effects, and creates a safety plan that includes naloxone for overdose reversal.
To prevent precipitated withdrawal, buprenorphine is typically started when short-acting opioids have worn off enough that mild to moderate withdrawal symptoms are present. Two common approaches exist:
The goal is comfortable, steady stabilization without a rushed timeline.
Switching to BRIXADI is usually straightforward. After reviewing the patient's current daily dose and stability, the clinician selects a weekly injection that matches their needs. Some patients transition to a monthly injection later once the right dose is confirmed. The first injection is given in-clinic with brief observation. A small bump under the skin at the injection site is normal and softens over days to weeks. Most patients experience similar or better craving control without the daily routine of films or tablets.
Moving from methadone to buprenorphine requires planning because of buprenorphine's strong receptor binding. The safest path typically involves a gradual methadone taper with close monitoring, careful timing of the first small buprenorphine dose to avoid precipitated withdrawal, and consideration of a micro-induction strategy if clinically appropriate. Transition to BRIXADI follows once buprenorphine is tolerated. The process is adjusted as needed to keep the patient comfortable and safe.
BRIXADI's flexibility is one of its strengths. (brixadihcp.com) Early in recovery, when cravings can fluctuate and life is unpredictable, the weekly option allows faster dose adjustments and more frequent check-ins for support, skills building, and relapse prevention. Once a patient is doing well on a steady weekly dose, conversion to monthly injections offers convenience for long-term maintenance. Dose strengths come in a range that the clinician individualizes. It is common to begin weekly, stabilize, and then move to a monthly plan, though some patients prefer to remain on weekly dosing for the added structure.
If a dose is missed, patients should contact their clinic promptly. There is often a safe window to administer the injection, and the care team will guide next steps.
BRIXADI is generally well tolerated, and most side effects are mild and improve as the body adjusts. Injection-site soreness, redness, itching, or a small lump that slowly fades are the most common reactions. Headache, constipation, nausea, sweating, and mild fatigue or sedation, especially early on, are also reported.
Seek care promptly if any of the following occur:
Medication interactions require attention. Combining buprenorphine with alcohol, benzodiazepines, or other sedatives increases the risk of dangerous sedation. When these medications are both clinically necessary, the approach involves close coordination, the lowest effective doses, and overdose education with naloxone. Because buprenorphine is metabolized by the liver, any history of hepatitis or liver disease should be disclosed, and labs may be checked periodically. Every provider a patient sees, including dentists and surgeons, should know they are on long-acting buprenorphine.
Medication is one pillar of recovery. With cravings quieter, many patients find space to rebuild routines and relationships. Carrying naloxone and ensuring that family or friends know how to use it is a practical safety step. Keeping injection appointments on the calendar and treating them as essential health visits helps maintain continuity. Prioritizing sleep, hydration, and adequate fiber supports energy and helps manage constipation. Counseling provides a space to practice coping skills for stress, triggers, and mood changes.
Driving and work are typically fine once a patient knows how the medication affects them. If sedation follows an injection, driving or hazardous tasks should be avoided until it passes.
Buprenorphine is a standard treatment during pregnancy; it reduces overdose risk and supports stable prenatal care. (acog.org) However, data on long-acting injections in pregnancy are more limited than for sublingual formulations. If pregnancy is possible, patients should tell their clinician so the risks and benefits can be reviewed and the safest path chosen for parent and baby. MOUD should never be stopped suddenly if pregnancy occurs; the care team should be contacted right away.
Surgery, dental work, and injury care are all possible while on long-acting buprenorphine, but management requires planning. For minor procedures, non-opioid strategies such as acetaminophen, NSAIDs, and local anesthetics often suffice. For more significant pain, short-term full-agonist opioids may be used with careful dosing and monitoring; because buprenorphine occupies receptors, higher-than-usual doses may be needed, and coordination with the surgical or anesthesia team is essential. Patients should never stop BRIXADI on their own before a procedure; the plan should be discussed with the prescriber and surgeon in advance.
All effective OUD treatments share one goal: reduce harm and support lasting recovery. Each option has trade-offs.
There is no single best option for everyone. The right choice is the one a patient can access, tolerate, and continue safely.
Because BRIXADI is administered in a clinic, coverage may fall under the medical benefit, pharmacy benefit, or a combination. Prior authorization is common. Scheduling follow-ups at the time of each injection helps avoid gaps in coverage. Patients who travel for work or family should tell their clinician in advance; early dosing, a local partner clinic, or a short-term weekly plan can often bridge a trip. Keeping a list of all medications and allergies accessible on a phone is useful for unexpected emergency or dental visits.
If cost is a concern, patient assistance programs and payment options are worth asking about. Uncertainty about coverage should not prevent someone from seeking care.
Showing up consistently matters: the dose works best when given on schedule. Being honest with the care team about cravings or slips allows dose, visit frequency, or counseling to be adjusted before a lapse becomes a larger problem. Sleep is a priority; recovering brains heal faster with regular rest. Filling the day with purpose, whether work, school, caregiving, volunteering, or exercise, reduces the high-risk state of boredom. Keeping naloxone on hand and ensuring that close contacts know how to use it remains important throughout maintenance. Recovery is not linear, and small setbacks are feedback, not failure.
There is no fixed right time to stop MOUD. Many people remain on buprenorphine for years because it keeps them safe, stable, and well. When a patient is thinking about tapering off BRIXADI, the conversation should cover several factors: at least several months of steady mood, housing, and work or school stability; minimal cravings and no recent lapses; strong coping skills and a dependable support network; and a plan for stress, grief, travel, and anniversaries of prior use.
Tapering from long-acting buprenorphine should be slow and collaborative. A common path steps down to a lower monthly dose, then to weekly for more control, and sometimes transitions briefly to sublingual buprenorphine for fine adjustments. Counseling, safety planning, and periodic check-ins continue throughout. If cravings return or life becomes turbulent, pausing or reversing the taper is a reasonable and appropriate response.
Will I feel the medication "kick in" after each shot? Most patients notice steady relief rather than a sudden effect. The goal is even coverage without highs or lows.
Can I still have surgery or dental work? Yes. Clinicians should be told about the long-acting buprenorphine so they can plan effective pain control.
What if I relapse while on BRIXADI? The care team should be told right away. The dose can be adjusted, support increased, and safety protected.
Is BRIXADI addictive? Buprenorphine is a treatment for addiction, not a substitute for it. Physical dependence, meaning the body expects the medication, is not the same as addiction, which involves compulsive use despite harm. When used as prescribed, it reduces harm and saves lives.
Healing Sky matches people with providers who offer evidence-based care for opioid use disorder, including long-acting injectable buprenorphine maintenance. If BRIXADI sounds like the stability you have been looking for, Healing Sky can connect you with a provider to begin the evaluation safely. Reach out to schedule a consultation.
Medically reviewed by Cynthia Abraham, D.O.
Read More
(NA)
Read More
(NA)
Read More
(NA)
Sign up now to get unrestricted access to Healing Sky's online mental health directory, resources, and more!
Sign up now
